Cabozantinib as a novel therapy for renal cell carcinoma.
Curr Oncol Rep
; 15(2): 76-82, 2013 Apr.
Article
em En
| MEDLINE
| ID: mdl-23292795
ABSTRACT
Cabozantinib/XL184 (Exelexis, Inc.) has demonstrated remarkable responses in kidney cancer. Preclinical results revealed VEGF, KIT and MET inhibition in a variety of solid tumors such as thyroid, ovarian, renal, lung, liver and prostate cancers. A phase II trial demonstrated efficacy in renal cancer with a 28 % objective response rate, stable disease rate of 62 % and median progression free survival of 14.7 months. Predominant toxicities of fatigue and diarrhea were noted. Dramatic responses in bone metastases (three of four patients) make the agent especially valuable for palliation in a disease, where presence of bone metastases is a predictor of worse survival. Cabozantinib is an emerging novel agent with promising activity in advanced kidney cancer. Randomized trials are planned in comparison with standard VEGF inhibitor therapy. Defining the role of MET overexpression would help patient selection and enrich and enhance the future evaluation of this targeted novel agent.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Piridinas
/
Carcinoma de Células Renais
/
Receptores Proteína Tirosina Quinases
/
Neoplasias Renais
/
Anilidas
/
Antineoplásicos
Tipo de estudo:
Clinical_trials
Idioma:
En
Revista:
Curr Oncol Rep
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Estados Unidos